Sanofi Aventis France has been charged by prosecutors in France with manslaughter over birth defects related to a drug prescribed around the world to treat epilepsy -- charges it denies and is challenging.
The charges relate to the drug sodium valproate, or Depakine as it is better known. Studies say the drug has caused disabilities in up to 30,000 children whose mothers took the medicine while pregnant.
The long-running case has also seen the pharmaceutical company charged with aggravated deceipt and causing involuntary harm.
Depakine has been on the market since 1967, and the company insists it had warned authorities of the drug's risks in the 1980s.
Separately, Sanofi has said that it is in "advanced discussions" with GSK and the European Union to supply up to 300 million doses of a COVID-19 vaccine. The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technology. The doses would be manufactured in European countries including France, Belgium, Germany and Italy.
Image: Sanofi Corporate
Latest News
-
BSI: Businesses don’t understand implications of net zero
-
HSE to increase COVID-secure spot checks
-
VIEW: Trade credit weaknesses remain despite government scheme
-
Government moves to increase pressure on late payers
-
2021 Predictions: Cyber carriers will become more selective
-
Flying taxis on horizon as Sompo and Flock join forces
Are property insurers ready for timber
The Structural Timber Association is gearing up to help all stakeholders in the construction supply chain to fully appreciate the advantages of building in timber, how to deliver such projects and most importantly to understand and manage the risks.
The changing face of BC and WAR
The working environment has changed quite dramatically for many over the last six months. With social distancing and the rise of homeworking, it is not just how businesses operate that has changed, but also how they recover. In this podcast we discuss some of the challenges created by the quick shift to home working, why the office may not have seen its last days and how the current environment can impact the ability of a business to recover.
© 2019 Perspective Publishing Privacy & Cookies
Recent Stories